Multiple studies have shown that immunotherapy combined with chemotherapy has the opportunity to become the treatment of choice for patients with advanced lung squamous cell carcinoma, regardless of PD-L1 expression or TMB level. This evidence concerns the gene CD274 and squamous cell lung carcinoma.